Tuesday’s Midday Movers: uniQure NV (QURE), Cree (CREE), Royal Gold (RGLD), United States Steel (X), Intercept Pharma (ICPT)

By Carrie Williams

So far Tuesday, October 15, NASDAQ is up 2.56% and the S&P is up 2.17%. Here are this morning’s most active stocks: uniQure NV (QUREResearch Report), Cree (CREEResearch Report), Royal Gold (RGLDResearch Report), United States Steel (XResearch Report) and Intercept Pharma (ICPTResearch Report).

uniQure NV is up 6.61% in midday trading to $44.70. Shares opened today at $41.93. The company has a 52-week low of $21.98 and a 52-week high of $82.49. On the Street’s front, the average 12-month analyst price target for the stock is $91.00, marking a 117.03% potential upside from current levels. In a report released yesterday, H.C. Wainwright analyst Debjit Chattopadhyay maintained a Buy rating on QURE, with a price target of $73.00, which represents a potential upside of 74% from where the stock is currently trading. Separately, on July 29, Guggenheim’s Whitney Ijem downgraded the stock to Hold . In the last 30 days, insiders have sold $224.9K worth of QURE shares. Over the last 3 months, the insider sentiment on uniQure NV has been negative based on 42 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Cree is up 5.59% in midday trading to $48.95. Shares opened today at $46.36. The company has a 52-week low of $34.52 and a 52-week high of $69.21. On the Street’s front, the average 12-month analyst price target for the stock is $54.00, marking a 16.48% potential upside from current levels. In a report issued on October 8, Canaccord Genuity analyst Jonathan Dorsheimer maintained a Buy rating on CREE, with a price target of $64.00, which represents a potential upside of 38% from where the stock is currently trading. Separately, on August 29, Banco BNP Paribas Brasil SA’s Jerome Ramel initiated coverage with a Sell rating on the stock . In the last 30 days, insiders have sold $1.12M worth of CREE shares. Over the last 3 months, the insider sentiment on Cree has been positive based on 28 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Royal Gold is down -5.58% in midday trading to $116.34. Shares opened today at $123.22. The company has a 52-week low of $70.16 and a 52-week high of $138.78. On the Street’s front, the average 12-month analyst price target for the stock is $117.38, marking a -4.74% potential downside from current levels. In a report issued on August 9, B.Riley FBR analyst Adam Graf maintained a Buy rating on RGLD, with a price target of $132.50, which represents a potential upside of 8% from where the stock is currently trading. Separately, on August 8, Cantor Fitzgerald’s Mike Kozak maintained a Hold rating on the stock and has a price target of $125.00. Over the last 3 months, the insider sentiment on Royal Gold has been negative based on 36 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

United States Steel is up 5.42% in midday trading to $11.67. Shares opened today at $11.07. The company has a 52-week low of $9.93 and a 52-week high of $29.84. On the Street’s front, the average 12-month analyst price target for the stock is $10.75, marking a -2.89% potential downside from current levels. In a report issued on October 2, BMO analyst David Gagliano maintained a Hold rating on X, with a price target of , which represents a potential upside of 8% from where the stock is currently trading. Separately, on September 19, Macquarie’s David Lipschitz downgraded the stock to Sell and has a price target of $9.00.

Intercept Pharma is up 5.1% in midday trading to $64.26. Shares opened today at $61.14. The company has a 52-week low of $56.76 and a 52-week high of $131.87. On the Street’s front, the average 12-month analyst price target for the stock is $150.60, marking a 146.32% potential upside from current levels. In a report issued on September 30, Robert W. Baird analyst Brian Skorney reiterated a Buy rating on ICPT, with a price target of $227.00, which implies an upside of 271% from current levels. Separately, on August 8, Stifel Nicolaus’ Derek Archila reiterated a Hold rating on the stock and has a price target of $86.00. In the last 30 days, insiders have sold $232.2K worth of ICPT shares. Over the last 3 months, the insider sentiment on Intercept Pharma has been positive based on 101 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>